Truist Securities adjusted its outlook for Sangamo BioSciences, reducing the price target on the company's shares to $5 from ...

4D Molecular Therapeutics is axing two clinical programs and cutting off funds for three other assets, with resources to be ...

This clinic started due to a specific Rare Genetic Kidney disease called Fabry Disease. Fabry Disease affects 1:40,000 individuals. This clinic is one of the country’s largest Fabry Disease clinics ...

Amicus Therapeutics’ first oral drug for the rare condition Fabry disease has been approved by the FDA, giving patients an alternative to conventional injected enzyme replacement therapy.

Fast Five Quiz: Fabry Disease Presentation and Diagnosis Would you be able to diagnose Fabry disease? Test your knowledge with this quick quiz. Medscape, April 06, 2021 Fast Five Quiz: Rheumatoid ...

Amicus Therapeutics FOLD announced preliminary total revenues for the fourth quarter and full-year 2024. The company’s top ...

"We are committed to delivering innovative therapies and solutions for people living with Fabry disease, their families and caregivers." A biopharmaceutical company, Protalix leverages its plant ...

The graduate engineer has Fabry disease, which damages the heart, kidneys and nervous system, and cannot access treatment in his home country. The Home Office says it still intends to remove him ...

Sangamo is focusing on finding a new partner for the hemophilia A program and is actively pursuing collaborations in the Fabry disease space, which has attracted significant interest from other ...

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on FOLD stock, giving a Buy rating on January 13.Stay Ahead of ...